JP2010535742A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010535742A5 JP2010535742A5 JP2010519468A JP2010519468A JP2010535742A5 JP 2010535742 A5 JP2010535742 A5 JP 2010535742A5 JP 2010519468 A JP2010519468 A JP 2010519468A JP 2010519468 A JP2010519468 A JP 2010519468A JP 2010535742 A5 JP2010535742 A5 JP 2010535742A5
- Authority
- JP
- Japan
- Prior art keywords
- olmesartan medoxomil
- hydrohalide
- acid
- hydrohalic acid
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002051 C09CA08 - Olmesartan medoxomil Substances 0.000 claims 22
- 229960001199 olmesartan medoxomil Drugs 0.000 claims 22
- UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 claims 19
- 239000002253 acid Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 6
- -1 C 6 alcohols Chemical class 0.000 claims 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 4
- 238000002441 X-ray diffraction Methods 0.000 claims 4
- 238000002329 infrared spectrum Methods 0.000 claims 4
- 238000002844 melting Methods 0.000 claims 4
- 230000008018 melting Effects 0.000 claims 4
- 239000003960 organic solvent Substances 0.000 claims 4
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- 238000000354 decomposition reaction Methods 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims 2
- 239000012296 anti-solvent Substances 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 238000004807 desolvation Methods 0.000 claims 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000004678 hydrides Chemical class 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 229940071870 hydroiodic acid Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07114004A EP2036904A1 (en) | 2007-08-08 | 2007-08-08 | A process for the preparation of olmesartan medoxomil |
| EP07114000A EP2022790A1 (en) | 2007-08-08 | 2007-08-08 | A process for the preparation or purification of olmesartan medoxomil |
| EP07114000.8 | 2007-08-08 | ||
| EP07114004.0 | 2007-08-08 | ||
| PCT/EP2008/060396 WO2009019303A2 (en) | 2007-08-08 | 2008-08-07 | A process for the preparation or purification of olmesartan medoxomil |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010535742A JP2010535742A (ja) | 2010-11-25 |
| JP2010535742A5 true JP2010535742A5 (enExample) | 2011-09-22 |
| JP5685082B2 JP5685082B2 (ja) | 2015-03-18 |
Family
ID=39789494
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010519468A Expired - Fee Related JP5685082B2 (ja) | 2007-08-08 | 2008-08-07 | オルメサルタンメドキソミルの調製または精製の方法 |
| JP2010519469A Pending JP2010535743A (ja) | 2007-08-08 | 2008-08-07 | オルメサルタンメドキソミルの調製のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010519469A Pending JP2010535743A (ja) | 2007-08-08 | 2008-08-07 | オルメサルタンメドキソミルの調製のための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8592474B2 (enExample) |
| EP (2) | EP2176253B1 (enExample) |
| JP (2) | JP5685082B2 (enExample) |
| CN (2) | CN101778843A (enExample) |
| AT (1) | ATE528305T1 (enExample) |
| BR (2) | BRPI0815111A2 (enExample) |
| CA (2) | CA2707365A1 (enExample) |
| SI (1) | SI2176253T1 (enExample) |
| WO (2) | WO2009019303A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE528305T1 (de) * | 2007-08-08 | 2011-10-15 | Lek Pharmaceuticals | Verfahren zur herstellung oder reinigung von olmesartan-medoxomil oder von olmesartan- medoxomil-hydrohalid-salz |
| EP2298763B1 (en) | 2008-06-09 | 2015-03-25 | Daiichi Sankyo Company, Limited | Method for producing 1-biphenylmethylimidazole compound |
| US8859600B2 (en) * | 2009-04-28 | 2014-10-14 | Daiichi Sankyo Company, Limited | Acetone solvate crystals of trityl olmesartan medoxomil |
| CA2759163C (en) | 2009-04-28 | 2015-02-17 | Daiichi Sankyo Company, Limited | Method for producing olmesartan medoxomil |
| WO2011007368A2 (en) * | 2009-07-14 | 2011-01-20 | Cadila Healthcare Limited | An improved process for preparation of olmesartan |
| US20120184751A1 (en) * | 2009-07-31 | 2012-07-19 | Ranbaxy Laboratories Limited | Polymorphic form of olmesartan medoxomil |
| WO2011021224A2 (en) * | 2009-08-19 | 2011-02-24 | Msn Laboratories Limited | Process for (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl4-(1-hydroxy-1-methylethyl)-2-propyl-1-[4-[2-tetrazol-5-yl)phenyl]phenyl]methylimidazole-5-carboxylate |
| CZ303188B6 (cs) * | 2010-10-29 | 2012-05-16 | Zentiva, K.S. | Zpusob výroby olmesartanu medoxomilu |
| KR101275092B1 (ko) * | 2011-05-19 | 2013-06-17 | 한미정밀화학주식회사 | 아질사르탄의 개선된 제조방법 |
| CN102351849B (zh) * | 2011-10-26 | 2013-10-02 | 齐鲁天和惠世制药有限公司 | 一种奥美沙坦酯的制备方法 |
| CN103304550B (zh) * | 2012-03-16 | 2016-01-27 | 湖南欧亚生物有限公司 | 一种奥美沙坦酯的制备方法 |
| CN103319461A (zh) * | 2013-07-02 | 2013-09-25 | 临海天宇药业有限公司 | 奥美沙坦酯中间体的制备方法以及奥美沙坦酯的合成方法 |
| CN103435602A (zh) * | 2013-07-31 | 2013-12-11 | 山东省医学科学院药物研究所 | 一种奥美沙坦酯的制备方法 |
| CN104262332A (zh) * | 2014-09-16 | 2015-01-07 | 上海信谊百路达药业有限公司 | 一种奥美沙坦酯的制备方法 |
| CN104447715B (zh) * | 2014-11-28 | 2017-06-20 | 山东新华制药股份有限公司 | 奥美沙坦酯的制备方法 |
| CN104817546B (zh) * | 2015-05-20 | 2020-02-07 | 浙江华海药业股份有限公司 | 一种奥美沙坦酯母液回收的方法 |
| CN107311990B (zh) * | 2017-07-25 | 2021-09-03 | 浙江华海致诚药业有限公司 | 一种奥美沙坦酯的制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5616599A (en) * | 1991-02-21 | 1997-04-01 | Sankyo Company, Limited | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
| ES2155827T3 (es) * | 1992-06-02 | 2001-06-01 | Sankyo Co | 4-carboxiimidazoles como antagonistas de la angiotensina ii y su uso terapeutico. |
| JP2001226372A (ja) * | 1999-12-06 | 2001-08-21 | Sumika Fine Chemicals Co Ltd | ロサルタンの結晶性または結晶化された酸付加塩およびロサルタンの精製方法 |
| ITMI20032338A1 (it) * | 2003-11-28 | 2005-05-29 | Dinamite Dipharma S P A In Forma A Bbreviata Diph | Composti feniltetrazolici. |
| WO2006029056A1 (en) | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries Ltd. | Preparation of olmesartan medoxomil |
| KR20090102883A (ko) * | 2004-09-02 | 2009-09-30 | 테바 파마슈티컬 인더스트리즈 리미티드 | 올메살탄 메독소밀의 정제 |
| GB2419592A (en) * | 2004-10-26 | 2006-05-03 | Cipla Ltd | Process for the preparation of irbesartan hydrochloride |
| US20060281800A1 (en) * | 2005-04-12 | 2006-12-14 | Glenmark Pharmaceuticals Limited | Polymorphic form of olmesartan and process for its preparation |
| CA2616466A1 (en) | 2005-07-29 | 2007-02-15 | Krka | Process for the preparation of olmesartan medoxomil |
| EP1816131A1 (en) | 2006-02-06 | 2007-08-08 | KRKA, tovarna zdravil, d.d., Novo mesto | Process for the preparation of olmesartan medoxomil |
| WO2007052301A2 (en) | 2005-08-31 | 2007-05-10 | Alembic Limited | Process for the preparation of irbesartan |
| EP1801111B1 (en) * | 2005-12-20 | 2014-07-16 | LEK Pharmaceuticals d.d. | Novel polymorph forms of olmesartan medoxomil |
| CA2654218C (en) * | 2006-04-07 | 2014-07-22 | Lek Pharmaceuticals D.D. | Process for the preparation of pure irbesartan |
| WO2007148344A2 (en) | 2006-06-19 | 2007-12-27 | Matrix Laboratories Limited | Process for the preparation of olmesartan medoxomil |
| KR101458369B1 (ko) | 2006-10-09 | 2014-11-05 | 씨아이피엘에이 엘티디. | 트리틸 올메사탄 메독소밀 및 올메사탄 메독소밀의 제조방법 |
| ATE528305T1 (de) * | 2007-08-08 | 2011-10-15 | Lek Pharmaceuticals | Verfahren zur herstellung oder reinigung von olmesartan-medoxomil oder von olmesartan- medoxomil-hydrohalid-salz |
-
2008
- 2008-08-07 AT AT08786993T patent/ATE528305T1/de not_active IP Right Cessation
- 2008-08-07 CA CA2707365A patent/CA2707365A1/en not_active Abandoned
- 2008-08-07 EP EP08786993A patent/EP2176253B1/en not_active Not-in-force
- 2008-08-07 BR BRPI0815111-3A2A patent/BRPI0815111A2/pt not_active Application Discontinuation
- 2008-08-07 EP EP08786996.2A patent/EP2173741B1/en not_active Not-in-force
- 2008-08-07 SI SI200830507T patent/SI2176253T1/sl unknown
- 2008-08-07 US US12/672,267 patent/US8592474B2/en not_active Expired - Fee Related
- 2008-08-07 JP JP2010519468A patent/JP5685082B2/ja not_active Expired - Fee Related
- 2008-08-07 CN CN200880102268A patent/CN101778843A/zh active Pending
- 2008-08-07 BR BRPI0815134-2A2A patent/BRPI0815134A2/pt not_active Application Discontinuation
- 2008-08-07 CA CA2707334A patent/CA2707334C/en not_active Expired - Fee Related
- 2008-08-07 CN CN200880102267.4A patent/CN101778842B/zh not_active Expired - Fee Related
- 2008-08-07 WO PCT/EP2008/060396 patent/WO2009019303A2/en not_active Ceased
- 2008-08-07 WO PCT/EP2008/060400 patent/WO2009019304A1/en not_active Ceased
- 2008-08-07 JP JP2010519469A patent/JP2010535743A/ja active Pending
- 2008-08-07 US US12/672,264 patent/US20110224271A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021201339B2 (en) | Fenfluramine compositions and methods of preparing the same | |
| CN105524046B (zh) | 制备吡咯化合物的方法 | |
| JP2009541334A5 (enExample) | ||
| JP2011513485A5 (enExample) | ||
| JP2016034968A5 (enExample) | ||
| JP2017522276A5 (enExample) | ||
| JP2007532560A5 (enExample) | ||
| JP2010509334A5 (enExample) | ||
| JP2004513106A (ja) | 塩酸ベンラファキシンの結晶形 | |
| CN1984905B (zh) | 作为凝血酶受体拮抗剂的约束喜巴辛类似物 | |
| JP2020502077A5 (enExample) | ||
| JP2016510767A5 (enExample) | ||
| CN1277611A (zh) | 3－取代的四氢吡啶并嘧啶酮衍生物,它们的制备方法和应用 | |
| EP2109601A2 (en) | Preparation of darifenacin and its salts | |
| JP6657223B2 (ja) | 医薬調製物用の（ｓ）−ｎ−（３−（６−イソプロポキシピリジン−３−イル）−１ｈ−インダゾール−５−イル）−１−（２−（４−（４−（１−メチル−１ｈ−１，２，４−トリアゾール−３−イル）フェニル）−３，６−ジヒドロピリジン−１（２ｈ）−イル）−２−オキソエチル）−３−（メチルチオ）ピロリジン−３−カルボキサミド組成物 | |
| JP2007508393A5 (enExample) | ||
| JP2010540440A5 (enExample) | ||
| CN100413854C (zh) | 一种曲美他嗪及其药用盐的制备方法 | |
| WO2005019199A1 (en) | Amorphous duloxetine hydrochloride | |
| JP2024516199A (ja) | バルベナジンの合成方法 | |
| JP2009536638A (ja) | アトルバスタチンマグネシウムの結晶性形状ｂ４及びその方法 | |
| US8193217B2 (en) | Polymorphic form of granisetron hydrochloride and methods of making the same | |
| WO2004099142A1 (en) | Hydrobromide salt of benzyl-piperidylmethyl-indanone and its polymorphs | |
| JP2009505945A5 (enExample) | ||
| JP2013516496A5 (enExample) |